Trial Information

Summary: A Phase I Trial of Radiommunotherapy (Y90 cT8.66), Gemcitabine and Hepatic Arterial Infusion of Fudr for Metastatic Colorectal Carcinoma to the Liver

You have been asked to participate in this research study because you have colorectal cancer that has spread to your liver. The main purpose of this study is to determine the highest dose of the standard chemotherapy drug FUdR that can be given directly into the liver in combination with the standard chemotherapy drug gemcitabine and the investigational drug Y-90-DTPA-Chimeric T84.66 Anti-CEA (a radioactive antibody) after first removing as much of the tumors as possible by surgery. Your participation in this study is expected to last up to approximately one year for treatment. After your treatment on this study is over, your medical condition will be followed. Anticipated length of follow-up on this study is approximately six months.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:31:12 PM